AI’s greatest impact will not only be on the drugs we discover, but also on how quickly, affordably, and effectively we bring them to patients. Transforming drug development will take more than technology or any single company. That is why we are excited to publish the full paper detailing the development and testing of our CMC Document Processor (CDP), created alongside @AnthropicAI. When tested on a complete Phase 2 GMP batch record, CDP identified more major quality issues, provided more precise comments than human reviewers, and reduced review time by 89%. The healthier world we want to build is bigger than one drug or one company. Let’s build the future together. Read the paper: enveda.com/cmc-document-proc…

Patients cannot wait another day for tomorrow’s medicines. Today, bringing a drug to market can take more than 10 years and cost over $1 billion. A major contributor is the time and expense required to generate and review the documentation that helps to build medicines that are safe and effective. That is why we are thrilled to partner with @AnthropicAI to transform drug development, starting with our clinical-stage programs. Together, we built tools to address two major early-stage bottlenecks: preparing a complete IND package and reviewing CMC batch records for release. The results have been groundbreaking in speed, cost, and quality. Read more: anthropic.com/research/early…

Tech and startups are very much like sports: fast-paced, constant iteration, big bets and massive outcomes. So what happens when you get ESPN-like coverage of Tech? You get @tbpn. @jordihays and @johncoogan are at the bleeding edge of what's happening in tech, startups and venture capital, bringing sharp perspectives and candid conversations with the people building what's next. It's why we were so excited Enveda Founder & CEO @viswacolluru joined the show to speak about our recent $311M Series E and how we're bringing billions of years of evolutionary R&D to discover new medicines that serve the biggest indications people need and value. Watch the full conversation. #AI #Tech #Biotech

All of us have a stake in what the AI boom delivers. In @FastCompany, Enveda’s @viswacolluru and Bigyan Bista explore why better medicines could be among its largest payoffs. fastcompany.com/91613320/the… #AI #Biotech #LearningfromLife

We are excited to present at #EADV26 Late Breakers the mechanistic and biomarker data for our first-in-class oral treatment for atopic dermatitis and asthma, ENV-294. ENV-294 targets a previously unengaged pathway, deepens our understanding of the fundamental biology underlying the disease, and presents hope for patients looking for new treatments. Join us: Late-Breaker Oral Presentation: Title: A Previously Undrugged Target in Immune Therapeutics: Oral ENV-294 Provides First Clinical and Molecular Proof of Concept for RAC2 Modulation in Atopic Dermatitis (D3T01.4A) Presenter: Ester Del Duca, M.D., Ph.D., Laboratory of Inflammatory Skin Diseases, Department of Dermatology, Icahn School of Medicine at Mount Sinai in New York City Date/Time: Friday, October 2, 2026, 16:00-16:15 CEST / 10:00-10:15 EDT Room: Hall A, Austria Center Vienna Oral Presentation: Title: ENV-294, a First-in-Class Oral Rac2 Modulator, Demonstrates Deep, Durable Efficacy with a Favorable Safety Profile in Moderate-to-Severe Atopic Dermatitis: Results from a Phase 1b Open-Label Study (FC01.1E) Presenter: Leon Kircik, M.D., Clinical Professor of Dermatology, Icahn School of Medicine at Mount Sinai, New York; Adjunct Clinical Professor of Dermatology, Indiana University School of Medicine Date/Time: Thursday, October 1, 2026, 09:10-09:20 CEST / 03:10-03:20 EDT Room: Hall N, Austria Center Vienna Read more: businesswire.com/news/home/2…

Enveda on the @Nasdaq Tower in @TimesSquareNYC. This special moment was made even better by having our Founder and CEO, @viswacolluru there in person to take it in. The display marked our $311 million Series E and the years of work behind it: every experiment, every molecule, every late night, every setback that taught us something, and every hard problem solved by our team. The financing reflects the confidence an exceptional group of investors has placed in Enveda’s platform, pipeline, and long-term ambition. That confidence also carries a responsibility to put the capital to work with discipline and urgency, moving our medicines forward and continuing to turn life’s chemistry into better options for patients. Thank you to our friends at Nasdaq for marking the moment so beautifull y. #Enveda #LearningfromLife #AI #Biotech

Welcome to the new pharma. Built on billions of years of evolution. Learn more: Enveda.com

Enveda on the New York Stock Exchange cubes today! Grateful to our friends at the @NYSE, Eric Dimise and Johanna Grossman, for putting our $311M Series E up in lights in the financial heart of New York City. This raise opens the next chapter for Enveda as we advance our clinical-stage pipeline and keep turning nature's chemistry into medicines for millions of patients. Onward. #Enveda #LearningfromLife #AI #Biotech

Today we are announcing a $311M Series E to bring pharma into the 21st century. Enveda started with a thesis: a molecule that evolution has already refined is a better place to begin than one designed from scratch. This year, two first-in-class molecules discovered by Enveda (ENV-294 and ENV-308) had positive readouts in humans. Many more are behind them. We are grateful to @CatalioCapital for leading this round, to our new investors Durable Capital Partners, @ICONIQCapital, @lightspeedvp, Surveyor Capital (a Citadel company), accounts advised by @TRowePrice, @digitalisvc and Alderline Group, and to @BaillieGifford, @PremjiInvest, @trueventures, @KinnevikAB, @FPVventures, @_DimensionCap, @lifeforcecap and @Lux_Capital for continuing to back us. The best is yet to come… Read more: businesswire.com/news/home/2… #Biotech #AI #LearningfromLife

AI is now proving its potential to unlock new frontiers in drug discovery. At the World Medical Innovation Forum presented by @MassGenBrigham and @BankofAmerica, Enveda Founder & CEO Viswa Colluru, PhD will join an esteemed panel to explore how AI is changing what’s possible in drug discovery, from decoding complex chemistry found in nature to turning it into new drug leads, and what this new era means for the investors backing the next generation of drug discovery platforms. Investing in High Impact Drug Leads in the AI Era September 22 | Boston More: 2026.worldmedicalinnovation.… #WMIF2026 #DrugDiscovery #AI #Biotech

Being an Envedian is as much about who you are as it is about what you do. The best work comes from those who truly love what they do and who they do it with. Karina is one of the many people who make Enveda special, and why we’ve been recognized by @LovedWorkplace, @FastCompany + Wellhub and others. Thank you to all Envedians. #Biotech #Culture #Values

Founder + CEO of biotech firm @enveda shares why the most successful drugs in history trace back to living cells, and how his team built the world's first sequencer to decode them. Watch the full conversation with @viswacolluru: piped.video/YbelId-Pqog

Today on NYSE Live ⤵️ @commonsensebull, @KeyAdvisorsLLC @ThomasPerfumo, @krakenfx Kathy Kellert, @Vanguard_Group @codyplof, Winks Tune in 9AM ET for more. nitter.siddz.com/i/broadcasts/1dKrPrwEV…

We are making medicines that people need and want. The coverage around #ENV308, capturing some of the medicine of exercise in a pill, has been exciting and validating for metabolic health and life after GLP-1s. piped.video/q5PBYQH6_Pc

Colorado biotech Enveda reports preliminary results on a drug to help people maintain weight loss after GLP-1 use. Just don't call it exercise in a pill. trib.al/BZso0xb